Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
Study sponsor: Lakefront Biotherapeutics NV · LKFT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-11-20Actual
Enrollment · participants139Actual
Source updated2024-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.